Angelman Syndrome clinical trials at UCSF

1 research study open to eligible people

Angelman syndrome is a condition that affects a person's mental and physical development. UCSF is testing a drug named GTX-102 to understand its effect on the brain function of children with the disorder. The study examines how this drug works in cases related to certain genetic deletions.

Showing trials for

  • GTX-102 in Pediatric Subjects With AS

    open to eligible people ages 4-17

    The primary objective of this study is to evaluate the effect of GTX-102 in cognitive function in participants with deletion-type Angelman Syndrome (AS).

    San Francisco, California and other locations

Our lead scientists for Angelman Syndrome research studies include .

Last updated: